Antiarrhythmic drugs are medications that correct abnormal heart rhythms by changing how electrical signals travel through the heart. They work by blocking or modifying specific ion channels in heart muscle cells, which are the tiny gates that control the flow of sodium, potassium, and calcium. These charged particles moving in and out of cells are what generate each heartbeat, so adjusting their flow can slow a racing heart, stabilize an erratic one, or prevent dangerous rhythms from starting.
How Your Heart’s Electrical System Works
Every heartbeat begins as an electrical impulse that sweeps through the heart in a precise sequence. This impulse is created by ions (sodium, potassium, and calcium) flowing through channels in cell membranes in a cycle called the action potential. The cycle has distinct phases: a rapid upstroke as sodium rushes in, a plateau sustained by calcium, and a recovery phase as potassium flows out to reset the cell.
Arrhythmias happen when this cycle goes wrong. A cell might fire too quickly, an electrical signal might loop back on itself, or part of the heart might start generating its own rogue impulses. Antiarrhythmic drugs target specific points in this electrical cycle. Some slow the initial sodium surge to reduce how fast signals spread. Others extend the recovery period so the heart has more time to reset between beats. The goal is always the same: restore a stable, coordinated rhythm.
The Four Main Classes
Antiarrhythmic drugs are organized using the Vaughan Williams classification, which groups them by how they alter the heart’s electrical activity. The four classes used in everyday clinical practice each target a different ion channel or receptor.
Class I: Sodium Channel Blockers
These drugs slow the initial electrical surge that triggers each heartbeat by blocking sodium channels. They are subdivided into three groups based on how strongly and quickly they act. Class Ia drugs (like quinidine and disopyramide) moderately slow signal conduction and also lengthen the recovery period. Class Ib drugs (like lidocaine and mexiletine) have a milder effect on conduction and actually shorten recovery time, making them useful for certain ventricular rhythm problems. Class Ic drugs (like flecainide and propafenone) are the most potent sodium blockers, significantly slowing electrical conduction without much change to recovery time.
Class Ic agents carry a notable risk: in one retrospective study, flecainide and similar drugs combined with beta-blockers were associated with proarrhythmic events (new or worsened arrhythmias) in about 44% of treated patients. Because of this, they are generally reserved for people without significant structural heart disease.
Class II: Beta-Blockers
Rather than targeting ion channels directly, beta-blockers reduce the effect of adrenaline on the heart. By blocking beta-adrenergic receptors, drugs like propranolol, atenolol, and bisoprolol slow the heart rate and reduce the force of contraction. This makes them especially effective for arrhythmias triggered or worsened by stress, exercise, or other situations that spike adrenaline. They decrease the tendency of heart cells to fire spontaneously, which helps suppress extra beats and rapid rhythms. Beta-blockers are among the most widely prescribed antiarrhythmics because of their relatively favorable safety profile.
Class III: Potassium Channel Blockers
These drugs block potassium channels, which delays the recovery phase of each heartbeat. This effectively lengthens the time a heart cell needs before it can fire again, making it harder for rapid or chaotic rhythms to sustain themselves. Amiodarone, dronedarone, and sotalol are the best-known examples.
Amiodarone is often considered the most effective antiarrhythmic available and has one of the lowest rates of triggering new arrhythmias, around 3% in one study of 230 patients. Sotalol, which also has beta-blocking properties, showed a much higher proarrhythmic rate of roughly 44% in the same study. This stark difference is one reason amiodarone remains a go-to option for serious rhythm disorders despite its other side effects.
Class IV: Calcium Channel Blockers
Verapamil and diltiazem are the primary drugs in this class. They block calcium channels in the heart, which slows electrical conduction through the AV node, the gateway between the upper and lower chambers. This makes them particularly useful for controlling the heart rate in atrial fibrillation and for treating certain supraventricular tachycardias, where abnormal circuits loop through or near the AV node.
Which Arrhythmias They Treat
The choice of antiarrhythmic depends heavily on the type of rhythm problem and whether the heart has any underlying structural damage.
For atrial fibrillation, the most common sustained arrhythmia, the goal is often to restore and maintain a normal rhythm. Flecainide and propafenone work well in people with structurally normal hearts. Amiodarone and dronedarone are options when other drugs have failed or when there is underlying heart disease. For people with heart failure and reduced pumping function, the 2023 ACC/AHA guidelines now give catheter ablation a top-tier recommendation over drug therapy, based on studies showing ablation outperforms medications in this group.
For ventricular arrhythmias, which originate in the lower chambers and can be life-threatening, amiodarone and lidocaine are the most commonly used drugs. Beta-blockers also play a key role, especially in preventing sudden cardiac events in people with heart failure or after a heart attack. Class Ic drugs are generally avoided in ventricular arrhythmias when structural heart disease is present because of the elevated risk of making the rhythm worse.
Side Effects and Risks
The central paradox of antiarrhythmic drugs is that the same properties that correct an abnormal rhythm can sometimes create a new one. This is called proarrhythmia, and its risk varies dramatically between drugs. The risk climbs when the heart’s electrical recovery interval (measured on an ECG as the QT interval) stretches beyond 500 milliseconds, or when electrolyte levels, particularly potassium, magnesium, and calcium, are low.
Beyond proarrhythmia, each class carries its own side-effect profile. Beta-blockers commonly cause fatigue, dizziness, and cold extremities. Sotalol’s non-cardiac side effects resemble those of other beta-blockers, with fatigue and weakness being most common but no significant organ toxicity. Flecainide occasionally causes low white blood cell counts or liver problems, though both are uncommon.
Amiodarone deserves special attention because its side effects extend well beyond the heart. The drug accumulates in tissues throughout the body, which contributes to a uniquely broad toxicity profile:
- Lungs: About 1% of patients per year develop pulmonary toxicity, and 5% to 10% of those cases are fatal.
- Thyroid: Both overactive and underactive thyroid conditions can develop, and the onset is not usually related to dose.
- Liver: Roughly 25% of patients see a temporary rise in liver enzymes.
- Eyes: Corneal deposits causing blurred vision are common but typically reversible.
- Skin: Sun sensitivity and discoloration can occur due to the drug’s tendency to bind to cell membranes.
- Nervous system: Tremors, balance problems, insomnia, and vivid dreams are reported.
Amiodarone vs. Dronedarone
Dronedarone was developed as a modified version of amiodarone, specifically designed to reduce the organ toxicity that limits amiodarone’s long-term use. A large comparative study found that dronedarone had meaningfully lower rates of adverse events across several categories: 29% fewer heart and vascular side effects, 35% fewer respiratory problems, and 19% fewer gastrointestinal and liver issues compared to amiodarone. However, dronedarone is less potent at maintaining normal rhythm and is not suitable for patients with severe heart failure, where amiodarone remains the safer choice.
Monitoring During Treatment
Because antiarrhythmic drugs directly alter the heart’s electrical properties, ongoing monitoring is essential. Before starting treatment, a baseline ECG establishes your normal QT interval and heart rhythm pattern. Follow-up ECGs track whether the QT interval is drifting into a dangerous range. A QTc value at or above 500 milliseconds, or an increase of more than 60 milliseconds from baseline, is a red flag that the drug may be pushing the heart toward a dangerous rhythm called torsades de pointes.
Blood tests for potassium, magnesium, and calcium levels are also standard, since low levels of any of these electrolytes amplify the risk of drug-induced arrhythmias. For amiodarone specifically, regular thyroid function tests, liver enzyme checks, lung function assessments, and eye exams become part of routine care for as long as you take the medication. Kidney function matters too, especially for drugs like sotalol that are cleared by the kidneys, since impaired clearance can lead to drug accumulation and increased toxicity.